ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ZVRA / insiders
OLMA (29) ANL (46) BCAX (30) NVCT (37) ⌘ Pro Terminal →

Zevra Therapeutics Inc. (ZVRA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$10.10 -1.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.05

Zevra Therapeutics Inc. (ZVRA) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $610.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZVRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Zevra Therapeutics Inc. (NASDAQ: ZVRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $10.10 (-1.75% 1D, market cap $610.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZVRA ranks #532 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZVRA compare to OLMA and ANL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZVRA carries a Roarable D- (37/100 RQD), trailing P/E of 7.4x, gross margin of —, and ROIC of -32.3%. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -32.8%, cap $612.5M) and ANL (Adlai Nortye Group Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $615.0M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZVRA?
▼

Per ZVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434647), Zevra Therapeutics Inc. generated $176.2M in revenue (-27.7% YoY), $83.2M in net income, and -$2.4M in free cash flow against $284.7M in total assets and $61.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.05 (-0.51%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (4)Whales (6)SEC (13)Macro (7)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$16 Bull$9 Base$7 Bear
📬 FREE ZVRA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZVRA)Realized 20D OHLCV Swing Band: ±8.9%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY ZVRA SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (35% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (19% of score)

FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 45.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$10.39+0.8% Next Q
Q2 (-2Q)
42
Grade D$10.47-3.9% Next Q
Q3 (-1Q)
40
Grade D$10.06+0.4% Next Q
Current
37
Grade D-$10.10-8.1% Hist 90D α
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZVRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZVRA currently carries a cautious 37/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.12) and Max Pain ($10.61) forces dealer call-delta covering toward $15.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZVRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZVRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ZVRA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ZVRA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ZVRA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZVRA)

  • ✓Walkthrough of ZVRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ZVRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.50%📐 WEDGE COMPRESSION COIL
2026-11-03O $10.36H $10.36L $10.10C $10.10VOL 642.1K
RES: $10.92SUP: $9.49SMA50: $11.12SMA200: $10.76
$15.45$13.73$12.01$10.29$8.57RES $10.92SUP $9.49$10.102026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZVRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZVRA Butterfly Map → + Track ZVRA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-6.9%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ZVRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZVRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZVRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZVRA)

Health Care Rank #532 of 1016 ⚔️ OLMA vs ZVRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZVRA vs. OLMA, ANL, BCAX, NVCT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zevra Therapeutics Inc. (ZVRA) ranks #532 by composite RQD confidence (37/100, grade D-) and #413 by equity capitalization ($610.5M). Within this direct 5-issuer industry benchmark cohort, ZVRA leads on earnings valuation at 7.4x trailing P/E, while ZVRA leads on capital efficiency and profitability with -32.3% ROIC and — gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with ZVRA at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ZVRA ACTIVE
Zevra Therapeutics Inc.
D- 37/100 7.4x — -32.3% -1.75% $610.5M Benchmark Subject
OLMA
Olema Pharmaceuticals Inc.
E 29/100 — — -32.8% +1.00% $612.5M /olma-vs-zvra →
ANL
Adlai Nortye Group Ltd.
D 46/100 — — — -1.88% $615.0M /anl-vs-zvra →
BCAX
Bicara Therapeutics Inc.
E 30/100 — — -35.0% -13.14% $604.2M /bcax-vs-zvra →
NVCT
Nuvectis Pharma Inc.
D- 37/100 — — -35.0% +3.79% $602.7M /nvct-vs-zvra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001434647

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zevra Therapeutics Inc. (ZVRA) reported GAAP revenue of $176.2M (-27.7% vs. FY2024 revenue of $243.6M , and +26.9% cumulative change since FY2023) , GAAP net income of $83.2M, operating cash flow of -$1.6M, and free cash flow of -$2.4M (+96.5% YoY). On the balance sheet, ZVRA closed FY2025 with $284.7M in total assets against $61.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $176.2M $83.2M -$1.6M -$2.4M $284.7M $61.9M
FY2024 (FY) 2024-12-31 $243.6M -$105.5M -$69.7M -$69.7M $178.1M $59.5M
FY2023 (FY) 2023-12-31 $138.9M -$46.0M -$33.5M -$33.5M — —

3. ZVRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Zevra Therapeutics Inc. (NASDAQ: ZVRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $10.10 (-1.75% 1D, market cap $610.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZVRA ranks #532 in composite RQD confidence.

How does ZVRA compare to OLMA and ANL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZVRA carries a Roarable D- (37/100 RQD), trailing P/E of 7.4x, gross margin of —, and ROIC of -32.3%. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -32.8%, cap $612.5M) and ANL (Adlai Nortye Group Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $615.0M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZVRA?

Per ZVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434647), Zevra Therapeutics Inc. generated $176.2M in revenue (-27.7% YoY), $83.2M in net income, and -$2.4M in free cash flow against $284.7M in total assets and $61.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZVRA trading relative to its 50-day, 200-day, and 52-week technical levels?

ZVRA last traded at $10.10 (-1.75% on volume of 637,432 shares), positioning the stock -9.17% below its 50-day simple moving average ($11.12) and -6.13% below its 200-day simple moving average ($10.76). Across its 52-week range of $8.01 to $15.03, ZVRA sits at the 29.8% percentile with a 14-day RSI of 45.8 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($9.20 to $11.00).

Direct Sub-Reports: ZVRA RQD Cockpit ZVRA 12M Forecast ZVRA Earnings & Move ZVRA Dividends & DRIP ZVRA Insiders & 13F ZVRA Whale Options ZVRA Profit Sankey ZVRA News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

ZVRA — Zevra Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Zevra Therapeutics Inc. (ZVRA) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $10.10 (-1.75% 1D, market capitalization $610.5M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -32.3%, gross margin of —, operating margin of —, and free cash flow yield of -0.40%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of 0.40x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Zevra Therapeutics Inc. (ZVRA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company has a market capitalization of $0.6B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Zevra Therapeutics Inc. (ZVRA) reported $176.2M in annual revenue (up from $243.6M in FY2024, -27.7% YoY) and $83.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($138.9M revenue, -$46.0M net income) through FY2025, ZVRA scaled operating cash flow to -$1.6M and free cash flow to -$2.4M, backed by $284.7M in total assets against $61.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -0.40% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $8.01 – $15.03 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 7.4x trailing P/E against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary signals are mapped. — for supplier, customer, or sector-linkage analysis. Investors should monitor the European commercial outlook referenced in the news feed as the principal open second-order variable.

  • Key Question #1: Can ZVRA sustain or expand its — operating margin and -32.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $176.2M and free cash flow of -$2.4M, how will capital allocation balance growth reinvestment against $61.9M in total debt?
  • Key Question #3: How sensitive is ZVRA's 6.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ZVRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zevra Therapeutics Inc. (ZVRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZVRA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZVRA Bull vs. Bear Conversation Board — What's Your Call at $10.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZVRA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ZVRA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $13.26 (+29.0%)
📌 Pinned Debate

The stock trades at a P/E of 7.4 TTM and 6.9 forward, with the forensic balance sheet pillar scoring 13 out of 20 and debt-to-equity at

The street is overcomplicating Zevra Therapeutics Inc. (ZVRA). The stock trades at a P/E of 7.4 TTM and 6.9 forward, with the forensic balance sheet pillar scoring 13 out of 20 and debt-to-equity at 0.4.. With an RQD score of 37/100 (D-) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $11.10.

ArenaChamp_24 🐂 BULL

@FadeTheHype Fair point on 7.4x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $8.74 (-15.0%)
Spot @ $10.28

Return on invested capital is -32.3% and FCF yield is -0.4%, with operating income negative in both FY 2025 and FY 2024.

Return on invested capital is -32.3% and FCF yield is -0.4%, with operating income negative in both FY 2025 and FY 2024.. Look at the math on ZVRA: paying 7.4x trailing P/E for -32.3% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $9.05 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%